Patents by Inventor Naima Moustaid-Mousse

Naima Moustaid-Mousse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Screening for SUR1 antagonists using adipocytes
    Patent number: 6242200
    Abstract: The invention provides methods for identifying compounds and compositions useful in the regulation of weight, the treatment of obesity, diabetes and other insulin resistance-related disorders hypertension, cardiovascular disease and the like. The methods comprise the use of adipocytes and predipocytes in assays and screens for compounds or compositions of interest. The present invention recognizes the presence of the sulfonylurea receptor in adipocytes and its utility in identifying compounds and in treating obesity and other insulin resistance-related disorders. In addition to assaying for agonists and antagonists of the sulfonylurea receptor, the methods of the invention also provide for identifying novel calcium channels or other calcium regulatory channels that are selectively expressed in human adipocytes as compared to human preadipocytes and for screening adipocytes for compounds that selectively antagonize calcium.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: June 5, 2001
    Assignees: Zen Bio, Inc., The University of Tennessee Research Corporation
    Inventors: William O. Wilkison, Michael B. Zemel, Naima Moustaid-Mousse
  • Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
    Patent number: 6100047
    Abstract: The invention provides methods for identifying compounds and compositions useful in the regulation of weight, the treatment of obesity, diabetes and other insulin resistance-related disorders hypertension, cardiovascular disease and the like. The methods comprise the use of adipocytes and predipocytes in assays and screens for compounds or compositions of interest. The present invention recognizes the presence of the sulfonylurea receptor in adipocytes and its utility in identifying compounds and in treating obesity and other insulin resistance-related disorders. The methods of the invention also provide for identifying novel calcium channels or other calcium regulatory channels that are selectively expressed in human adipocytes as compared to human preadipocytes and for screening adipocytes for compounds that selectively antagonize calcium. These compounds may be used in the treatment of obesity and diabetes and other insulin resistance-related disorders.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: August 8, 2000
    Assignees: Zen Bio, Inc., The University of Tennessee Research Corporation
    Inventors: William O. Wilkison, Michael B. Zemel, Naima Moustaid-Mousse